Plain-English translation of NCT06763354 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are testing a new diagnostic tool called Gallium[68Ga]NOTA-DNA multivalent SGC8 injection to help doctors see and identify bladder tumors more clearly. The injection is used during a special imaging scan (PET/MR) to light up cancer cells, making them easier to spot. The goal is to see if this new method works as well as the standard surgical approach doctors currently use.
Current methods for finding bladder tumors require surgery to collect tissue samples and confirm diagnosis. This trial is exploring whether the new imaging injection could help doctors detect tumors without surgery, which could make diagnosis faster and less invasive for patients.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will have a medical history review, physical exam including vital signs, and a cystoscopy (standard bladder examination). Then you will receive an injection of the new imaging medication and undergo a PET/MR imaging scan to see how well it detects your bladder tumor. Researchers will monitor you for any side effects and compare the imaging results to your pathology findings from the cystoscopy.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China
Sponsor
RenJi Hospital
Enrollment target
~20 participants
Started
February 2025
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 85 Years
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Peifeng Liu
RenJi Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.